This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Idorsia Pharmaceuticals Ltd. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Andrew Croxford: Innovator in CCR6 Receptor Modulation
Introduction
Andrew Croxford is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target specific receptors in the body. His work is essential for advancing treatments for various diseases.
Latest Patents
Croxford holds a patent for "Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators." This invention relates to compounds of Formula (I), their synthesis, and their use as CCR6 receptor modulators for the treatment or prevention of various diseases, conditions, or disorders. This patent highlights his innovative approach to addressing complex medical challenges.
Career Highlights
Andrew Croxford is currently employed at Idorsia Pharmaceuticals Ltd., a company known for its commitment to developing innovative therapies. His role at Idorsia allows him to collaborate with other talented professionals in the pharmaceutical industry, contributing to groundbreaking research and development.
Collaborations
Croxford has worked alongside notable colleagues such as Oliver Allemann and Alexia Chavanton-Arpel. These collaborations have fostered an environment of creativity and innovation, leading to advancements in their respective fields.
Conclusion
Andrew Croxford's work in CCR6 receptor modulation exemplifies the impact of innovative thinking in the pharmaceutical industry. His contributions are paving the way for new treatments that can significantly improve patient outcomes.